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Coagulation, fibrinolysis, and platelet activation in
patients undergoing open and endovascular repair
of abdominal aortic aneurysm
Robert S. M. Davies, MBChB, MMEd, MRCS,a,b Mohamed Abdelhamid, MRCS,a,b
Michael L. Wall, MBChB, MRCS,b Rajiv K. Vohra, PhD, FRCS,b
Andrew W. Bradbury, BSc, MBA, MD, FRCSEd,a and
Donald J. Adam, MD, FRCSEd,a Birmingham, United Kingdom
Background: Endovascular aneurysm repair (EVAR) is associated with an improved perioperative mortality compared to
open surgical repair. This benefit may reflect reduced incidence of microvascular and macrovascular thrombotic
complications after EVAR.
Purpose: The purpose of this study was to review and compare the effects of abdominal aortic aneurysm (AAA), open
surgical repair, and EVAR on coagulation, fibrinolysis, and platelet activation.
Methods: AMEDLINE (1966-2010) and Cochrane library search for articles relating to the effects of AAA, open surgical
repair, and EVAR on hemostasis was performed utilizing and cross-linking terms such as clotting, fibrinolysis, AAA,
EVAR, and open surgical repair. Studies with a small cohort of patients (less than 7) or in which values of assessed
biomarkers were not included were rejected.
Results: AAA is associated with increased thrombin generation, activity, and fibrin turnover as evidenced by increased
plasma levels of thrombin-antithrombin III-complex (TAT), activated protein C-protein C inhibitor (APC-PCI),
fibrin-monomer-fibrinogen (FM-F), F12, fibrinogen, and D-dimer. The extent of hemostatic derangement correlates
with the volume of intraluminal thrombus. This procoagulant state is exaggerated in the immediate perioperative period
after both open surgical repair and EVAR, but is attenuated at medium-term follow-up although not normalized.
Conclusion: The resultant prothrombotic diathesis after open surgical repair and EVARmay account for the high level of
perioperative thrombotic complications. ( J Vasc Surg 2011;54:865-78.)
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tMajor surgery results in a perioperative prothrombotic
diathesis with elevated levels of factor VIII, fibrinogen,
thrombin-antithrombin III-complex (TAT) and von Wil-
lebrand factor (vWF), as well as deranged fibrinolysis and
platelet hyperactivity.1-7 Elective open surgical repair of
infrarenal abdominal aortic aneurysm (AAA) is associated
with an operative mortality rate of 3% to 10%.8-12 Ischemia
reperfusion injury results in a systemic inflammatory re-
sponse with microvascular and macrovascular thrombosis
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ultiple organ failure thereby accounting for the great
ajority of operative mortality.13,14
By contrast, endovascular aneurysm repair (EVAR) of an
AA avoids much of this physiological disturbance and by so
oing offers a safer alternative in anatomically suitable pa-
ients. Thus, the EVAR-1, EVAR-2, and Dutch Randomized
ndovascular Aneurysm Management trials reported a 60%
eduction in perioperative mortality with EVAR when com-
ared to open surgical repair.15-18 However, some authors
ave reported that EVAR promotes a systemic inflammatory
esponse andprothrombotic coagulopathy equal if not greater
han that witnessed after open surgical repair.19,20 It has been
ypothesized that this is secondary to cytokine release from
hrombus within the aneurysm sac either as a result of intro-
ucer and catheter manipulation or, possibly, ischemia after
AA exclusion.19,21 The presence of type II endoleaks
ay allow these moieties to reach the systemic circula-
ion and cause their deleterious effects. The use of con-
rast media has also been reported to induce arterial
ndothelial damage, and this may also be relevant to the
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September 2011866 Davies et aldevelopment of what has been termed “postimplantation
syndrome” after EVAR.22,23 It is clearly important for
vascular and endovascular surgeons to be aware of this
biology so that they can mitigate the risks of open
surgical repair or EVAR in their patients. The purpose of
this study, therefore, was to review and compare the
effects of AAA, open surgical repair, and EVAR on
Table I. Summary of studies investigating the association
fibrinolysis
Study Cases Controls Results format
Adam et al43 7a 0b Median (range) 4.85 (1
Adam et al14 9 0b Median (range) 2.80 (1
g/L
Al-Barjas
et al36
110 110 Median
(interquartile
range)
2.89 (2
Blann et al38 21 42 Mean  SD 3.6  1
Bradbury et al8 23 0b Median (range) 5.16 (2
Fowkes et al35 89 98 Median
(interquartile
range)
3.5 (2.9
Fisher et al46 22 0b Mean 365 mg
Holmberg
et al37
23 0b Median (range) 3.6 (1.9
Holmberg
et al50
23 20 Median (range)
Hosaka et al42 49 0b Mean  SD 336 
Ihara et al52 22 26 Mean  SD
Jelenska et al45 20 22 Mean  SD 4.2  7
Lee et al44 40 200 Median
(interquartile
range)
3.05 (2
g/L
Milne et al65 105 32 Mean  SD
Parry et al47 75  90 Variable 2.92 (0
Shindo et al40 43 0b Mean  SEM 300.2 
mg/d
Sofi et al54 438 438 Mean  SD
Singh et al39 263  2699  Mean  SD 3.72 (0
74  3350  Mean  SD 3.77 (0
Wallinder
et al51
40 41 Median
(interquartile
range)
Wanhainen
et al53
42 100 Mean  SD
Yamazumi
et al41
36 25 Mean  SD 326 
AAA, Abdominal aortic aneurysm; NA, not available; NS, not significant;
antigen.
aSymptomatic unruptured AAA.
bManufacturer’s range.
ctPA activity.coagulation, fibrinolysis, and platelet activation. cETHODS
AMEDLINE, EMBASE, andCochraneCentral Register
f Controlled Trials databases search for English language
rticles between January 1966 and August 2010 relating to
he effects of AAA, open surgical repair, and EVAR on hemo-
tasis was undertaken. The terms coagulation, coagulopathy,
een AAA and levels of fibrinogen and biomarkers of
Fibrinogen
Fibrinolysis
D-dimer
Controls P value Case
.9) g/L 1.5-4.0 g/L .033 1633 (753-3014)
ng/mL
.02) 1.5-4.0 g/L NA
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.01
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g/L 2.0-3.6 g/L NS
571 (60-1515)
g/L
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ng/mL
/dL 313  55 mg/dL .001 778  311 ng/mL
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ng/mL
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mol/L 3.32 (0.88)
mmol/L
.001
mol/L 3.43 (0.80)
mmol/L
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Volume 54, Number 3 Davies et al 867thrombotic were included. These were linkedwith terms such
as infrarenal or juxtarenal AAA, open repair, and EVAR.
Further articles were identified by followingMEDLINE links,
cross-referencing from the reference lists of major articles, and
by following citations for these studies. Studies were specifi-
cally rejected if (1) the patient cohort was less than 7 and (2)
values of assessed biomarkers of hemostasis were not included
in the presented results. The studies were then graded and
Table I. (Continued)
Fib
D-dimer tPA ag
Controls P value Case Co
630-850 ng/mL .005 1.7 (0.75-3.2)
IU/mLc
0.2-2.0
0.49 (0.14-3.2)
IU/mLc
0.2-2.0
93.0 (57.8-158.8)
ng/mL
.001 7.9 (6.0-11.1)
ng/mL
8.6 (6.8
ng/m
32 (10-536) g/L .01 10.2 (4.9-24.2)
g/mL
9.4 (2.9
g/m
1.0 g/mL NA
125.7  46.1
ng/mL
.0001
362  242 ng/mL .001
83 (67.5-129)
ng/mL
.001 8.5 (7-10.5) ng/mL 7.9 (5.8
ng/m
120.2 (106.9-134.2)
ng/mL
.001 9.12 (8.03-10.50)
ng/mL
8.80 (8.
ng/m
0.8 g/mL NA
86 (38-176) ng/mL .001 10.5 (8.6-14.8)
ng/mL
11.1 (8.
ng/m
13.6  4.7 g/mL 11.4 
g/m
1.0  1.2 g/mL .01prioritized according to the Oxford Centre for Evidence- Fased Medicine (2002) levels of evidence and grades of rec-
mmendations criteria.24
ESULTS
Studies examining the effect of AAA, open surgical
epair, and EVAR on blood coagulation, fibrinolysis, and
latelet activity are summarized in Tables I-VI. The coag-
lation cascade and fibrinolytic pathways are summarized in
sis
PAI-1
P value Case Controls P value
L .023 6.3 (3.2-15.4)
AU/mL
15 AU/mL .005
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hemostasis. AAAs are characterized by chronic inflamma-
tion and the presence of mural thrombus.25 In contrast to
atherosclerotic occlusive disease, blood flow is maintained
through the mural thrombus of an aortic aneurysm,
thereby providing an interface for exchange between the
systemic circulation and thrombus.25 The structure of the
thrombus is highly complex with a network of intercon-
necting canaliculi capable of delivering macromolecules
between the intraluminal and thrombus-arterial wall sur-
Table II. Summary of studies investigating the association
Study Cases Controls Results format
Adam et al43 7a 0b Median (range)
Adam et al14 9 0b Median (range)
Holmberg et al50 23 20 Median (range)
Hosaka et al42 49 0b Mean  SD
Ihara et al52 22 26 Mean  SD
Jelenska et al45 20 22 Mean  SD
Kölbel et al62 78 121 Median (range; 10th-
90th percentiles)
Parry et al47 75  90 Variable
Shindo et al40 43 0b Mean  SEM
Wallinder et al51 40 41 Median (interquartile
range)
Yamazumi et al41 36 25 Mean  SD
AAA, Abdominal aortic aneurysm; APC-PCI, activated protein C-protein C
product; TAT, thrombin-antithrombin III-complex.
aSymptomatic unruptured AAA.
bManufacturer’s range.
Table III. Summary of studies investigating the associatio
Study Cases Controls Results forma
Adam et al43 7a 0b Median (range)
Blann et al38 21 42 Mean  SD
Bradbury et al8 23 0b Median (range)
Fowkes et al35 89 98 Median (interquartile
Holmberg et al50 23 20 Median (range)
Ihara et al52 22 26 Mean  SD
Milne et al65 105 32 Mean  SD
Shindo et al40 43 0b Mean  SEM
Wallinder et al50 40 41 Median (interquartile
Yamazumi et al41 36 25 Mean  SD
AAA, Abdominal aortic aneurysm; NA, not available; sP-selectin, soluble P-
aSymptomatic unruptured AAA.
bManufacturer’s range.faces. The canaliculi often contain cellular infiltrates, in- pluding neutrophils, macrophages, and platelets, often in a
tate of degranulation. This may lead to consumption of
latelets and coagulation factors to such an extent that a
ubclinical disseminated intravascular coagulation may ex-
st.26 Thus, the mural thrombus represents a biologically
ctive entity with the ability to trap polymorphonuclear
eukocytes, absorb circulating plasma components, and
ggregate platelets as well as being implicated as a source of
roteolysis and fibrinolytic activity thought to be implicit in
AA progression.25,27,28 Furthermore, it has been pro-
een AAA and biomarkers of thrombin generation
Thrombin generation
TAT F12
Case Controls P value Case
2.1 (1.1-5.2)
nmol/L
(6.6-180.4)
/L
1.0-4.0 g/L NA 2.2 (0.7-7.1)
nmol/L
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/L
2.6 (2.0-5.6)
g/L
.01 2.2 (0.9-4.6) nM
 11.3
/mL
3.5 ng/mL NA
 16/9
/mL
2.6  1.3
ng/mL
.0001
1.17  0.36 nM
(2.68-8.7)
/mL
1.89 (1.48-2.49)
ng/mL
.001 1.33 (0.98-1.79)
ng/mL
3.8-9.1)
/mL
2.9 (2.1-3.9)
g/mL
.001 0.8 (0.6-1.1)
nmol/L
 13.6
/mL
3.8  2.2
ng/mL
.01
itor; F12, prothrombin fragments 1 and 2; FDP, fibrinogen degradation
tween AAA and vWF, platelet count, and sP-selectin
vWF
Case Controls P value
123  37 IU/dL 113  32 IU/dL .001
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in; vWF, von Willebrand factor.betw
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act as solid catalyst between substrates transported through
the thrombus and proteases originating from the arterial
wall.28
Several studies have examined the effects of AAAs on
direct and indirect biomarkers of thrombin generation,
fibrinolysis, and platelet activity (Tables I-III).
An elevated level of plasma fibrinogen is an indepen-
dent risk factor for stroke (cerebrovascular accident) and
myocardial infarction as well as cardiovascular mortali-
Table II. Continued
Thrombi
F12 FDP
Controls P value Case Controls
0.4-1.1 nmol/L .001
0.4-1.1 nmol/L NA
1.2 (0.5-3.1) nM .05
0.99  0.28 nM .001
0.82 (0.75-0.90)
ng/mL
.004
718.6  138.2
ng/mL
100 ng/mL
0.8 (0.6-1.0)
nmol/L
.05
11.6  12.0
g/mL
3.6  2.0 g/
Table III. Continued
Platelet count
Case Controls P valu
183 (75-292)  109/L 150-350  109/L .05
204 (140-293)  109/L 150-350  109/L .05
215  47.5  109/L 269  57  109/L .000
17.9  5.7  103/mm3 15.7-34.2  103/mm3 NA
216 (176-242)  109/L 207 (177-238)  109/L .05
19.6  5.4  104/L 23.7  6.1  104/L .05ty.29-31 An association between elevated fibrinogen and Ltherosclerotic peripheral arterial disease has been widely
eported, and elevated levels of plasma fibrinogen are found
n patients who subsequently develop peripheral arterial
isease.30,32-34 The association between intact AAAs and
lasma fibrinogen levels has been extensively investigat-
d8,35-47 (Table I). Seven of 14 studies have reported
ignificantly elevated fibrinogen levels in patients with
symptomatic AAAs. The three studies with the largest
ohorts all demonstrate increased levels of plasma fibrino-
en in patients with AAAs.35,36,39 On multivariate analysis,
eration
APC-PCI
P value Case Controls P value
0.45 (0.24-1.47)
g/L
0.15 (0.10-0.23)
g/L
.0001
NA
.01
sP-selectin
Case Controls P value
325 (155-4253) ng/mL 202 (80-440) ng/mL .001n gen
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September 2011870 Davies et alAAA and plasma fibrinogen. Singh et al39 reported similar
findings but only in males.
Hosaka et al42 reported elevated levels of both fibrin-
ogen and fibrin-monomer-fibrinogen (FM-F) complex
in patients with AAAs. During the cleavage of fibrinogen
by thrombin, fibrinopeptide A and B are released to
create fibrin monomer (FM), which undergoes polymer-
ization to form insoluble fibrin clots.48 When a pro-
thrombotic state exists and thrombin generation is high,
FM forms soluble complexes with fibrinogen (FM-F
complex) due to excess plasma fibrinogen.49 Thus, ele-
vated levels of FM-F represent heightened thrombin
activity.
Adam et al14 reported significantly elevated levels of
plasma fibrinogen in patients with symptomatic, nonrup-
tured AAAs. In a separate study, Adam et al43 reported no
difference in preoperative plasma fibrinogen levels between
those patients with ruptured and asymptomatic intact
AAAs. However, these studies involved small numbers of
patients and used the manufacturer’s reference range for
comparison as opposed to controls.
Thirteen studies have investigated the association be-
tween AAAs and fibrinolysis.35,40-45,47,50-54 (Table I).
Eleven studies assessed the impact of AAAs on plasma
D-dimer levels. The degradation of fibrin by plasmin ulti-
mately results in the formation of two fragment-D mole-
cules that covalently link to form a dimer (D-dimer). Thus,
the presence of D-dimer in the circulation represents on-
going clot formation and fibrinolysis. All studies report
elevated levels of plasma D-dimer in patients with AAAs.
On multivariate analysis, both Lee et al44 and Parry et al47
reported an independent association between circulating
D-dimer levels and AAAs.
Tissue plasminogen activator (tPA) is released from
vascular endothelium in response to thrombin generation
and becomes incorporated into the fibrin clot as it forms.
Table IV. Summary of studies investigating the associatio
Biomarker Study
Maximum diameter
of AAA
APC-PCI Kölbel et al62 r  .22, P  .001
D-dimer Shindo et al40 r  .208, P  NS
Wallinder et al51 r  .427, P  .001
Yamazumi et al41 r  .644, P  .0001 r 
F-TFPI Yamazumi et al41 r  .408, P  .016 r 
FDP Shindo et al40 r  .208, P  NS
Yamazumi et al41 r  .561, P  .0009
Fibrinogen Al-Barjas et al36 r  .323, P  .01
FM-FC Hosaka et al42 r  .128, P  .381
PAI-ag Aho et al68
PIC Yamazumi et al41 r  .413, P  .0146
TAT Wallinder et al51 r  .28, P  .018
Yamazumi et al41 r  .566, P  .001 r 
AAA, Abdominal aortic aneurysm; APC-PCI, activated protein C-protein C
degradation product; FM-FC, fibrin monomer-fibrinogen complex; NS, n
inhibitor complex; TAT, thrombin-antithrombin III-complex.When bound to fibrin, tPA is a potent activator of plasmin- lgen and is, therefore, a marker of fibrinolysis. Plasmino-
en activator inhibitor (PAI)-1 is also released from the
ascular endothelium in the presence of thrombin and, by
nhibiting tPA, acts to maintain a balance between clot
ormation and lysis. Six studies have reported the effect of
AAs on both D-dimer levels and tPA and/or PAI-
.35,43,44,47,50,51 The majority of studies report no differ-
nce in circulating tPA antigen levels in patients with and
ithout an AAA. The one exception is Wanhainen et al53
ho report elevated levels of tPA antigen in patients with
creen-detected AAAs. The tPA antigen levels reflect both
he unbound, active tPA and the bound, inactive tPA/
AI-1 complexes. Therefore, it is important to measure
PA activity as opposed to tPA antigen to avoid the paradox
n which elevated levels of tPA antigen are associated with a
rocoagulant state due to increased PAI-1 activity.14 Only
hree studies have analyzed both tPA antigen and PAI-1
ctivity levels, and all three studies report no significant
ifference compared to their control populations.47,50,51
dam et al43 are the only group to report tPA activity and
AI-1 activity levels which were comparable to the manu-
acturer’s normal reference range in patients with symp-
omatic, non-ruptured AAAs.
Thrombin plays a central role in the initiation of coag-
lation and platelet activation.More recently, thrombin has
een implicated in smooth muscle cell mitogenesis, with
ntimal vascular smooth muscle cells showing increased
hrombin receptor expression.55 The conversion of pro-
hrombin to thrombin by prothrombinase complex results
n the production of a degradation product with a half-life
f 90 minutes; prothrombin fragment (PF) 1  2.56
hrombin released through this enzymatic process is inac-
ivated by antithrombin to form a TAT III-complex.57
hus, PF1  2 and TAT are biomarkers of coagulation
ctivation and thrombin generation. This review identified
ight studies that reported on the effect of AAAs on the
ween AAA morphology and biomarkers of hemostasis
angle along
th of AAA
Maximum thickness of
intraluminal AAA
thrombus
Total intraluminal
AAA thrombus
volume
r  .123, P  .142
r  .208, P  NS
1, P  .009 r  .650, P  .0001
3, P  .0006
r  .171, P  NS
r  .513, P  .0024
r  .323, P  .05
r  .233, P  .125
r  .51, P  .007
r  .484, P  .042
6, P  .0305 r  .677, P  .0001
itor; F-TFPI, free form of tissue factor pathway inhibitor; FDP, fibrinogen
nificant; PAI-ag, plasminogen activator inhibitor antigen; PIC, plasminn bet
Worst
leng
.41
.58
.36
inhibevels of one or both of these biomarkers41-43,45,47,50-52
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been demonstrated in men with small AAAs 55 mm in
diameter.47 Wallinder et al51 reported elevated levels of
TAT, but normal levels of PF1  2: this may be explained
by the short half-life of PF1  2 such that elevated TAT
levels are more indicative of ongoing thrombosis, whereas
PF1  2 may be more reflective of a single acute throm-
botic event.
Activated protein C (APC) is a natural anticoagulant
and is produced on the surface of intact endothelium after
the binding of thrombin to the endothelial cell cofactor
thrombomodulin.58 APC in the presence of protein S
cofactor limits thrombin production to the site of endothe-
lial injury.59,60 APC is inactivated by binding to protein C
inhibitor (PCI) to form activated protein C-protein C
inhibitor (APC-PCI) complex. This complex is detectable
in the blood for 20 minutes after formation and is a
sensitive indicator of thrombin generation.61 Kölbel et al62
reported a threefold increase in median APC-PCI complex
levels in patients with AAAs when compared to healthy
controls. Thus, an AAA would seem to be associated with
periods of acute thrombus formation on a background of
chronically increased thrombin generation.
Adhesion of platelets to exposed subendothelial collagen
leads to platelet activation and recruitment. This interaction is
mediated by vWF through its platelet receptor glycoprotein
(GP)-Ib.63 Activated platelets release prothrombotic media-
tors from dense bodies and alpha-granules that include vWF,
adenosine diphosphate, and thromboxane-A2; are rich in Fac-
torVa andFactorVIIa receptors; and undergo aggregation by
the binding of fibrinogen to platelet GPIIb/IIIa receptors on
adjacent platelets.64 Thus, the central role of platelet-vessel
wall interaction is the initiation and progression of thrombo-
sis. Seven studies have reported on the effects of AAAs on
platelets.38,40,41,43,45,51,65 Three studies reported signifi-
cantly lower levels of platelets in patients with AAAs. Milne
et al,65 in addition to demonstrating a lower platelet count,
found that patients with an AAA had elevated levels of
glycocalicin, a biomarker for GP-Ib levels. This may sug-
gest increased activation and destruction of platelets as a
result of adherence and incorporation into the aneurysm
thrombus. This would appear to be supported by Mu-
kaiyama et al66 who demonstrated uptake of radiolabeled
platelets by the AAA thrombus.
Platelets activated through exposure to subendothelial
collagenwithout concomitant aggregation at the site of injury
are removed from the circulation by the reticuloendothelial
system irrespective of platelet age.67 Thus, the AAA thrombus
may also induce platelet activation without platelet adhesion
leading to their subsequent destruction and GP-1b release.
The findings by Blann et al38 of increased levels of soluble
P-selectin, a marker of platelet activation, and vWF, would
support the theory of increased platelet activation.
Association between abdominal aortic aneurysm
morphology and hemostasis. Seven studies have reported
on the correlation between AAAmaximum diameter, throm-
bus volume, andmarkers of hemostasis36,40-42,51,68-70 (Table
IV). Some authors have demonstrated a correlation be- aween AAA size and total volume/maximum thrombus
hickness and the aforementioned changes in thrombin
eneration and fibrinolysis. By contrast, Kölbel et al69 failed
o show a correlation between APC-PCI levels and throm-
us volume or thrombus intraluminal surface area. Yama-
umi et al41 reported a correlation between AAA tortuosity
nd markers of thrombosis which may represent the associa-
ion between blood flow velocity changes, particularly turbu-
ent flow, and red blood cell (RBC) activation.71 Shindo et
l40 reported a correlation between RBC counts and the AAA
umen volume. Activated RBCs release adenosine diphos-
hate resulting in platelet aggregation and activation.72 The
onsumptive coagulopathy, resulting from the thrombus
ass, and the abnormal flow field in a tortuous lumen may
oth contribute to the hemostatic derangement in patients
ith AAAs.
The effect of open surgical repair on biomarkers of
emostasis. Major surgery is known toproduce a prothrom-
otic derangement with raised levels of factor VIII, fibrino-
en, TAT, vWF, platelet hyperactivity, and evidence of de-
anged fibrinolysis.1-7 Patients undergoing lower limb
urgical revascularization exhibit defective endogenous fi-
rinolytic activity, with increased levels of PAI-1 and tPA
ntigen, that return to preoperative levels by 1 week postpro-
edure.73-75
Studies reporting the effect of open surgical AAA repair
n hemostasis are summarized in Table V. Aho et al68 re-
orted significantly elevated levels of PF1  2 at 72 hours
ostsurgery compared to preoperative levels. There was a
onsignificant trend toward elevated levels of TAT, D-dimer,
PA antigen, and PAI antigen within the first 72 hours post-
urgery. These biomarkers returned to preoperative levels by 3
onths postprocedure, but remained elevated when com-
ared to healthy individuals suggestive of ongoing upregula-
ion of thrombin generation and fibrinolysis. Yamazumi et
l41 reported significantly lower levels of TAT andD-dimer at
months postrepair when compared to preoperative levels.
olmberg et al50 reported similar findings with elevated peri-
perative levels of TAT and PF1  2 which returned to
reoperative levels by 1-week postsurgery, but remaining ele-
ated compared to age-matched controls. In a separate study,
he same group reported that open surgical repair attenuating
he preoperative thrombotic derangement in the long-term
ith a reduction in TAT and D-dimer levels at a median
ollow-up of 26 months.76 However, the values remained
lightly higher than the normal healthy reference ranges sug-
esting ongoing hemostatic derangement despite thrombus
olume reduction.
The effect of endovascular aneurysm repair on bio-
arkers of hemostasis. Five studies have reported the
ffects of EVAR on hemostasis20,68,77-79 (Table VI). Serino
t al79 reported the short-term effects of EVAR on circu-
ating D-dimer levels in nine patients assessed preopera-
ively and day 4 postoperatively. D-dimer levels were ele-
ated in seven patients and decreased in two patients. The
edian level for the entire patient cohort did not demon-
trate a statistically significant difference between baseline
nd day 4 postoperation. This lack of statistical significance
p
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significant decrease in levels of platelets, fibrinogen, plas-
minogen, and prothrombin activity in patients undergoing
EVAR during the first 10 days postprocedure. This was
coupled with increased D-dimer and fibrinogen degrada-
Table V. Summary of studies investigating the effects of o
Biomarker Study Controls (units)
D-dimer Holmberg et al50 32 (10-536) g/L
Yamazumi et al41 1.0  1.2 g/mL
F12 Aho et al68 0.4-1.1 nmol/mL
Holmberg et al76 1.2 (0.5-3.1) nM
Holmberg et al50 1.2 (0.5-3.1) nM
FDP Yamazumi et al41 3.6  2.0 g/mL
Fibrinogen Aho et al68 1.7-4 g/La
Holmberg et al37 2.0-3.6 g/La
Yamazumi et al41 298  63 mg/dL
PAI ag Aho et al68 4-43 ng/mL
Holmberg et al50 4.7 (2.0-30.9) IU/mL
Platelet count Bradbury et al8 150-350  109/La
Yamazumi et al41 23.7  6.1  104/L
TAT Holmberg et al76 2.6 (2.0-5.6) g/L
Holmberg et al50 2.6 (2.0-5.6) g/L
Yamazumi et al41 3.8  2.2 ng/mL
tPA ag Aho et al68 1-20 ng/mL
Holmberg et al50 9.4 (2.9-19.0) g/mL
F12, Prothrombin fragments 1 and 2; FDP, fibrinogen degradation prod
thrombin-antithrombin III-complex; tPA ag, tissue plasminogen activator a
aManufacturer’s range.
bMean follow-up of 26 months (19-37).
Table VI. Summary of studies investigating the effects of
open repair
Biomarker Study
Type of
repair Controls (units)
D-dimer Monaco et al77 EVAR 450 ng/mLa
Serino et al79 EVAR 238  180 ng/mL
F12 Aho et al68 OR 0.4-1.1 nmol/mLa
EVAR
FDP Monaco et al77 EVAR 100 ng/mLa
Fibrinogen Aho et al68 OR 1.7-4 g/La
EVAR
Odegard
et al78
OR NA g/L
EVAR
Monaco et al77 EVAR 160-350 mg/dLa
PAI ag Aho et al68 OR 4-43 ng/mLa
EVAR
Platelet
count
Englberger
et al20
OR NA  109/L
EVAR 226  46
Monaco et al77 EVAR 130-340  103/dLa
tPA ag Aho et al68 OR 1-20 ng/mLa
EVAR
EVAR, Endovascular aneurysm repair; F12, prothrombin fragments 1 and
OR, open surgical repair; PAI ag, plasminogen activator inhibitor antigen;
aManufacturer’s range.tion product (FDP) levels suggestive of coagulation factor/ 6latelet consumption coupled with hyper-fibrinolysis dur-
ng the perioperative period in patients undergoing EVAR.
y 1-month post-EVAR, all biomarkers returned to preop-
rative levels with the exception of fibrinogen, which
eaked at 1-month and remained significantly elevated at
surgery on biomarkers of hemostasis
Preoperative value
24 hours
Value P value
11 (60-1275)
7.7  6.7
1.6  0.6 1.5  1.2 NS
.2 (0.9-4.6)
.4 (0.0-4.6)
11.6  12.0
3.9  0.8 3.5  0.7 NS
.6 (1.9-6.3)
326  77
18.8  6.0 32.4  13.3 .05
.6 (2.0-29.3)
92 (179-51)  109/L 187 (103-364)  109/L .001
19.6  5.4  104
.5 (2.6-30.3)
.5 (2.6-26.1)
17.4  13.6
9.7  2.6 14.3  4.9 .05
.3 (7.6-15.3)
S, not significant; PAI ag, plasminogen activator inhibitor antigen; TAT,
.
R on biomarkers of hemostasis and comparing them to
eoperative
value
Intra-
group
P value
24 hours
Inter-
group
P value Value
Inter-
group
P value
78  93.3 428.44  147.3 .01
63  521
g/mL
1.6  0.6 NS 1.5  1.2 NS NS
1.4  0.4 2.0  1.0 NS
6.3  1.3 11.2  3.8 .01
3.9  0.8 NS 3.5  0.7 NS NS
3.7  0.6 3.5  0.8 NS
9.6  50.6 159.4  44.9 .01
8.8  6.0 NS 32.4  13.3 .05 NS
6.5  6.4 24.5  8.5 .05
32  52 0.82 143  52 0.41
65  56
3.2  52.9 190.9  48.4 .05
9.7  2.6 NS 14.3  4.9 .05 NS
8.5  3.1 11.4  4.1 .05
P, fibrinogen degradation product; NA, not available; NS, not significant;
g, tissue plasminogen activator antigen.pen
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EVAR on hemostasis. Engleberger et al20 reported elevated
levels of markers of thrombin activity (fibrinopeptide A and
FM), thrombin formation (TAT) and fibrinolysis (D-
dimer) in both groups during the perioperative period with
Table V. Continued
72 hours 1 week
Value P value Value P value
2.0  0.9 .05 1.9  0.8 NS
2.7 (1.5-5.7) NS
7.1  2.0 .05 5.9  1.3 NS
5.6 (3.3-8.4) .001
27.9  6.2 NS 25.9  10.7 NS
11.8 (4.4  31.3) NS
13.6  4.3 NS 11.2  4.6 NS
Table VI. Continued
72 hours 5-7 days post-operative
Value
Intra-
group
P value
Inter-
group
P value Value
Intra-
group
P value
Inter-
grou
P val
420.5  149.8 .05
799  443 .19
2.0  0.9 .05 NS 1.9  0.8 NS NS
2.3  0.9 .05 2.0  0.7 NS
12.0  3.4 .01
7.1  2.0 .05 NS 5.9  1.3 NS NS
6.1  1.6 .05 6.1  2.1 NS
5.8 (4.9-6.9) .001 NS
5.8 (5.0-6.7) .001
187.3  4.7 .01
27.9  6.2 NS NS 25.9  10.7 NS NS
21.3  8.2 NS 25.3  8.0 NS NS
229  75 .98
229  74
170.6  34.7 .001
13.6  4.3 NS NS 11.2  4.6 NS NS
9.9  4.3 NS 10.3  4.9 NSreturn to preoperative values by postoperative day 5. Dur- dng this period, intergroup comparison revealed signifi-
antly elevated levels of thrombin activity and formation in
he EVAR group. Aho et al68 reported similar changes in
he perioperative period with elevated levels of markers for
hrombin formation (TAT, F1  2) and fibrinolysis (D-
3 months 12 months
Value P value Value P value
39 (23-326) .05
.6  3.5 .01
.4  0.6 NS
1.2 (0.8-3.0)b NS
.6  4.6 .17
.8  0.4 NS
1  55 .75
.4  6.0 NS
9.9 (2.0-54.5) NS
.2  5.0  104 .05
3.8 (2.7-16.2)b .05
.4  4.5 .01
.1  2.8 NS
12.5 (6.6-14.9) NS
3 months 6 months
Value
Intra-
group
P value
Inter-
group
P value Value
Intra-
group
P value
Inter-
group
P value
265.9  86.9 .05
1.4  0.6 NS
1.7  0.6 NS
6.0  1.0 .05
3.8  0.4 NS NS
3.6  0.7 NS
348.8  79.7 .01
5.4  6.0 NS NS
8.6  6.4 NS
237.8  60.3 .05
9.1  2.8 NS NS
8.7  3.2 NS4
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EVAR group compared to the open group (day 1 vs day 3).
All markers of hemostasis returned to preoperative levels by
1 week postoperation with the exception of D-dimer. D-
dimer increased in both groups after surgery and remained
above normal values at 3 months. However, compared to
preoperative levels, only the EVAR group demonstrated
a significant increase in D-dimer at 3 months.68 Fibrin-
ogen decreased in both groups during the first 24 hours
postoperatively, but thereafter increased such that at 72
hours it was significantly elevated compared to preoper-
ative values, but no intergroup difference was found.
Odegård et al78 reported similar findings in the periop-
Fig 1. Coagulation cascade. Biomarkers described in t
APC-PCI, activated protein C-protein C inhibitor comp
1 and 2; FM-F, fibrin monomer-fibrinogen complex; P
tissue factor; TM-IIa, thrombo-modulin-thrombin co
Willebrand factor.erative period for both EVAR and open repair. These lhanges in fibrinogen can be explained by consumption
nd/or depletion due to operative blood loss during the
rst 24 hours, followed by an increase in levels due to
ngoing inflammation associated with the endoprosthe-
is/graft as indicated by elevated levels of C-reactive
rotein and interleukin (IL)-6.68
Platelet counts decreased in the perioperative period
n three studies assessing the effects of EVAR on hemo-
tasis.20,68,77 Two comparative studies reported the de-
rease to be more pronounced after open repair.20,68 By
-week postoperative, both studies reported platelet
ounts being comparable to baseline levels in both the
VAR and open cohorts. Aho et al68 reported P-selectin
iew are highlighted in red. APC, Activated protein C;
TIII, antithrombin III; F12, prothrombin fragments
telets; PS, proteins; SP-selectin, soluble P-selectin; TF,
x; TAT, thrombin-antithrombin complex; vWF, vonhe rev
lex; A
lt, pla
mpleevels as reducing during the first 3 days postoperative
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selectin levels measured at 3 months were elevated in the
EVAR group.
DISCUSSION
AAA is associated with increased thrombin generation,
thrombin activity, and fibrin turnover as evidenced by
increased plasma levels of TAT, APC-PCI, FM-F, PF1 2,
fibrinogen, and D-dimer. Increased fibrin turnover within
the intraluminal AAA thrombus has been reported, and this
review has demonstrated that the majority of publications
report a positive correlation between the extent of hemo-
static derangement and AAA size and thrombus load.25
Thus, the prothrombotic diathesis witnessed in this patient
population may be secondary to continuous intraluminal
thrombus remodeling.
Open surgical repair causes significant hemostatic de-
rangement within the first postoperative week with in-
creased thrombin generation and activity and increased
fibrin turnover. By 3months postrepair, the prothrombotic
diathesis was similar to or reduced compared to the preop-
erative state but is not resolved completely with TAT and
D-dimer levels remaining elevated compared to healthy
controls. Although suggestive that the prosthetic graft itself
is capable of inducing a prothrombotic derangement, other
factors, including widespread atherosclerotic disease, may
contribute to the ongoing hemostatic derangement.80-82
High levels of cytokines have been found in stored RBC
concentrates, including IL-1, IL-6, and tumor necrosis
factor alpha.83 Cytokines may be potent coagulation stim-
ulators and thus the volume of blood transfusion may
contribute to the perioperative coagulation derangement
Fig 2. Diagrammatic representation of the fibrinolytic p
red. FDP, Fibrinogen degradation product; PAI-1, pla
complex; tPA, tissue plasminogen activator.witnessed after aneurysm repair.37 Increasing age has also teen reported to influence biomarkers of coagulation and
brinolysis.84,85
EVAR is associated with activation of the coagulation and
brinolytic pathways and platelet consumption in the periop-
rative period. Thrombin generation may be enhanced after
VAR compared to open repair.20 As with open repair, the
emostatic derangement improves over the first 3 months,
ut does not return to normal levels.
Although EVAR is less surgically traumatic than open
epair, this does not result in reduced hemostatic derange-
ent. Contrast media used in EVAR causes endothelial cell
njury and platelet activation.22,23,86 The passage of guide-
ires and catheters may injure the vessel endothelium causing
levated levels of thrombin generation and activity.87,88 The
otal prosthetic surface area exposed to the systemic circula-
ion following EVAR is greater than standard straight graft
pen surgical repair potentially inducing greater homeostatic
erangement. The aneurysm sac thrombus, with its proin-
ammatory properties, is removed with open repair but is not
emoved inEVAR. In the absence of an endoleak, exclusionof
he aneurysm sac from the circulation will result in complete
ac thrombosis with increased coagulation and fibrinolysis
ctivation and platelet consumption. In the presence of a type
endoleak, partial sac thrombosis occurs and the aneurysm
hrombus forms a sumpof proinflammatorymediators, which
emain in contact with the systemic circulation.
In summary, AAA is associated with a prothrombotic
iathesis proportional to the volume of intraluminal throm-
us. The procoagulant state is exaggerated in the immedi-
te perioperative period after both open and endovascular
epair, but is attenuated at medium-term follow-up, al-
y. Biomarkers described in the review are highlighted in
gen activator inhibitor type-1; PIC, plasmin inhibitorathwa
sminohough not normalized.
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